What does it actually take to move proven postpartum haemorrhage innovations into routine care? At Devex Impact House @ UNGA81, country experiences from Nigeria, Ghana, Kenya and India showed some of the practical work already underway: incorporating PPH interventions into national policy, financing commodities, strengthening provider capacity, adapting implementation to different settings and using local evidence to guide scale-up. This carousel pulls together some of the concrete approaches shared during the session. Read more in the thread below 👇

Every woman deserves to give birth in a health system that is prepared to prevent, detect and respond to postpartum haemorrhage (PPH). Yet, postpartum haemorrhage remains one of the biggest threats to women’s lives during childbirth globally. According to WHO, an estimated 27 million women experience excessive bleeding after birth every year, with nearly 43,000 women dying from it. As we mark World PPH Day, the 2026 focus on “Translating evidence to action” is a timely reminder that generating evidence is only the beginning. The real impact comes when evidence reaches policies, procurement systems, health facilities and, ultimately, the women who need lifesaving care. Through the Smiles for Mothers project, SCIDaR recently conducted a multi-state retrospective observational study to compare the real-world effectiveness and cost consequence of uterotonics for PPH prevention. The study analysed data from 7 states, 55 health facilities and 3,093 vaginal births between July 2024 and February 2026. The findings showed that PPH incidence was 2–3 times higher with oxytocin and oxytocin-misoprostol compared to HSC. Follow-on uterotonics were required in fewer women with HSC, while the need for blood transfusion followed a similar trend. And while HSC had a higher upfront unit cost, the average total cost per woman was lowest in the HSC group, with accrued savings as uptake increased. For us, these findings are not merely numbers. They raise a practical question. How do we jointly turn this evidence into action? That means prioritising HSC in national and state guidelines and procurement as a smart maternal health investment option that can reduce PPH-related maternal deaths. It means investing in evidence, policy, sustainable financing and procurement, and implementation support to accelerate the scale-up of HSC for PPH prevention. And it means women seeking care early and asking their provider about HSC to give them access to a reliable uterotonic. The evidence is one part of the journey. Turning that evidence into reliable access, informed decisions and better care is where lives can be saved. #WorldPPHDay #EndPPH #TranslatingEvidenceToAction #PostpartumHaemorrhage #MaternalHealth #SmilesForMothers #EvidenceToAction #MaternalMortality

Some projects leave behind more than results. They leave behind experience, lessons and a foundation for what comes next. Before ASPIRE, there was ACHIEVE. Launched in 2017, ACHIEVE worked to expand access to HIV testing, treatment and care through private healthcare facilities across FCT, Nasarawa and Rivers. The work reached hundreds of thousands of people and helped strengthen HIV services across the supported states. Building on that experience came, then came ASPIRE to further strengthen HIV services and expand access to care, while supporting areas including cervical cancer screening, prevention of mother-to-child transmission and gender-based violence services. From one chapter to the next, the work continues to evolve. As we celebrate 15 years, we’re spotlighting some of the projects that have shaped our journey and the impact we continue to build on. Read more in the thread below 👇